Answers are grounded in this paper and cite their sources.
Background: Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, has been considered a potential treatment for severe COVID-19 cases. However, data on its effectiveness remain limited. Objectives: This study aims to evaluate the outcomes of using TCZ in patients with severe COVID-19 during the fifth wave of the pandemic. Methods: This retrospective cohort study was conducted on 114 patients with severe COVID-19 who were hospitalized in the ICU at Sayyad Shirazi Hospital in Gorgan, Iran, during the fifth wave. The patients were divided into two groups: 57 received TCZ along with standard treatment (remdesivir and corticosteroids), while 57 received only standard treatments. Results: The mean age of the participants was 53.02 ± 17.29 years, with 54.4% being female. The mean length of hospitalization was 20.16 ± 17.30 days. Statistical analysis showed no significant differences regarding age (P = 0.34), gender (P = 0.25), or length of hospitalization (P = 0.84). Additionally, 43.9% of the participants had underlying health conditions, with no significant difference in their distribution (P = 0.70). The intubation rate was 3.5% in the TCZ group compared to 5.3% in the control group, with no significant association between the two groups (P = 0.64). Mortality rates were 47.4% (27 patients) in the TCZ group and 56.1% (32 patients) in the control group, with statistical analysis revealing no significant difference between the two groups (P = 0.34). However, in patients aged 60 years and older, the mortality rate was significantly higher in the control group than in the TCZ group (P = 0.03). Conclusion: The use of TCZ in severe COVID-19 patients hospitalized in the ICU was associated with a reduced mortality risk among patients aged 60 years and older.
No takes yet. Share an insight, caveat, or question.
Khodabakhshi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: